MRI data and genomic data are telling us different things about prostate cancer risk

A new paper just published on line in the journal PLoS One is entitled, “Association between a 17-gene genomic prostate score and a multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)”. … READ MORE …

Is LI-ESWT an effective treatment for ED subsequent to prostate cancer therapy

On our social network yesterday, a new member asked about a form of treatment called “GAINSWave” for men with erectile dysfunction (ED) after treatment for localized prostate cancer. We had never heard of GAINSWave prior to this question. … READ MORE …

Radio-guided surgery in the treatment of recurrent, initially localized prostate cancer

The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …

Abiraterone acetate vs. enzalutamide: a head-to-head study in men with CRPC

Apparently a group of Japanese researchers determined a while ago that we need to know whether abiraterone acetate (Zytiga) or enzalutamide (Xtandi) is the better drug for first-line treatment of chemotherapy-naive patients with castration-resistant prostate cancer (CRPC) — whether it is metastatic or non-metastatic in type. … READ MORE …

Does Lu-177-PSMA-617 increase survival?

We have enthusiastically reported the encouraging outcomes of the early clinical trials of the radiopharmaceutical Lu-177-PSMA, most recently at this link. Based on reduction in PSA levels, it performs well. But medicines have no real benefit if all they do is treat PSA. We want medicines that increase survival. … READ MORE …

Germline genetics and different responses to different types of ADT

Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …

Do men with mCRPC need to stay on ADT along with their abiraterone acetate?

On and off over the past few years your sitemaster has raised the question of whether there is any real clinical benefit to maintaining men on standard androgen deprivation therapy (ADT) once they become castrate resistant and are switched to treatment with newer drugs like abiraterone acetate (Zytiga) or enzalutamide (Xtandi). … READ MORE …